Our Company
Our Company
Company Philosophy
Corporate Compliance
Management
Responsibility
Board of Directors
PRODUCTS
ROLVEDON™ (eflapegrastim-xnst)
Development Pipeline
Pipeline
Poziotinib
Clinical Trials
Glossary
Investor Relations
Investor Relations
Press Releases
Events and Presentations
Corporate Governance
Corporate Governance
Management
Board of Directors
Committee Composition
Insider Transactions
Annual Report and Proxy Information
Financial Information
Financial Information
SEC Filings
10K Annual Reports
Quarterly Results
Financial Statements
Stock Information
Stock Information
Historic Stock Lookup
Investment Calculator
Stock-Split History
Analyst Coverage
Ownership Profile
Investor FAQs
Medical Affairs
Medical Affairs
Medical Information
Expanded Access Program
Careers
Contact Us
Expanded Access Program
Home
Expanded Access Program
Spectrum Pharmaceuticals is not accepting any new patients until further notice to the poziotinib EAP.
For additional information on the poziotinib EAP program please email
eap@sppirx.com
